Orange Book product · Brand (NDA)
TOSYMRA
SUMATRIPTAN
At a glance
Jan 25, 2019
Approved
Brand (NDA)
Application
Not listed
TE code
9
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 25, 2019
7 yr 6 mo ago
Patent 8268791 expires
Listed drug product patent expiration.
May 09, 2026
1 mo ago
Patent 8440631 expires
Listed drug product patent expiration.
May 09, 2026
1 mo ago
Patent 9283280 expires
Listed drug product patent expiration.
May 09, 2026
1 mo ago
Today
Patent 10603305 expires
Listed drug product patent expiration.
Jun 16, 2030
in 4 yr 1 mo
Patent 11337962 expires
Listed drug product patent expiration.
Jun 16, 2030
in 4 yr 1 mo
Patent 12090139 expires
Listed drug product patent expiration.
Jun 16, 2030
in 4 yr 1 mo
Patent 9610280 expires
Listed drug product patent expiration.
Jun 16, 2030
in 4 yr 1 mo
Patent 9974770 expires
Listed drug product patent expiration.
Jun 16, 2030
in 4 yr 1 mo
Patent 9211282 expires
Listed drug product patent expiration.
Jul 19, 2031
in 5 yr 2 mo
Pharmaceutical detail
Active ingredient
SUMATRIPTAN
Strength
10MG/SPRAY
Dosage form
SPRAY
Route
NASAL
TE code
Not listed
Application
NDA 210884
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (9)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8268791 | May 09, 2026 | 1 mo ago | Product |
| 8440631 | May 09, 2026 | 1 mo ago | ProductU-1719 |
| 9283280 | May 09, 2026 | 1 mo ago | Product |
| 10603305 | Jun 16, 2030 | in 4 yr 1 mo | ProductU-1719 |
| 11337962 | Jun 16, 2030 | in 4 yr 1 mo | ProductU-1719 |
| 12090139 | Jun 16, 2030 | in 4 yr 1 mo | Product |
| 9610280 | Jun 16, 2030 | in 4 yr 1 mo | ProductU-1719 |
| 9974770 | Jun 16, 2030 | in 4 yr 1 mo | ProductU-1719 |
| 9211282 | Jul 19, 2031 | in 5 yr 2 mo | ProductU-1719 |
